Bank of America Upgrades Integer (NYSE:ITGR) to Buy

Bank of America upgraded shares of Integer (NYSE:ITGR) from a neutral rating to a buy rating in a report released on Monday, MarketBeat.com reports. They currently have $135.00 price target on the medical equipment provider’s stock, up from their prior price target of $105.00.

A number of other analysts have also commented on ITGR. Benchmark boosted their target price on Integer from $105.00 to $130.00 and gave the company a buy rating in a research report on Thursday, March 28th. KeyCorp boosted their target price on Integer from $123.00 to $139.00 and gave the company an overweight rating in a research report on Tuesday, April 9th. Finally, CL King assumed coverage on Integer in a research report on Thursday, March 14th. They issued a buy rating and a $137.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Integer currently has an average rating of Moderate Buy and an average target price of $120.50.

Integer Stock Down 0.7 %

Shares of NYSE:ITGR opened at $118.49 on Monday. The company has a market capitalization of $3.97 billion, a price-to-earnings ratio of 44.05, a P/E/G ratio of 1.50 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The business’s 50-day moving average is $111.36 and its 200-day moving average is $98.08. Integer has a 1 year low of $69.40 and a 1 year high of $121.53.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.05. The company had revenue of $413.15 million for the quarter, compared to the consensus estimate of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.11 EPS. Equities research analysts predict that Integer will post 5.28 earnings per share for the current year.

Institutional Trading of Integer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Guidance Capital Inc. bought a new stake in Integer during the 1st quarter worth approximately $500,000. Congress Asset Management Co. MA increased its holdings in Integer by 7.5% during the 1st quarter. Congress Asset Management Co. MA now owns 453,260 shares of the medical equipment provider’s stock worth $52,886,000 after purchasing an additional 31,736 shares in the last quarter. Canandaigua National Bank & Trust Co. bought a new stake in Integer during the 1st quarter worth approximately $233,000. HighPoint Advisor Group LLC bought a new stake in Integer during the 4th quarter worth approximately $221,000. Finally, Quadrature Capital Ltd bought a new stake in Integer during the 4th quarter worth approximately $378,000. 99.29% of the stock is owned by institutional investors.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.